These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14606390)

  • 1. [Which patient needs an aldosterone antagonist?].
    Schultheiss
    MMW Fortschr Med; 2003 Apr; 145(16):6. PubMed ID: 14606390
    [No Abstract]   [Full Text] [Related]  

  • 2. [Eplerenone for treatment of heart failure].
    Yoshimura M
    Nihon Rinsho; 2007 May; 65 Suppl 5():153-8. PubMed ID: 17569313
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy of an aldosterone receptor blocker eplerenone in high risk survivors of acute myocardial infarction with signs of heart failure: results of EPHESUS].
    Trifonov IR
    Kardiologiia; 2003; 43(6):71-2. PubMed ID: 12974260
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

  • 5. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of selective aldosterone antagonists.
    Weinberger MH
    Curr Hypertens Rep; 2004 Oct; 6(5):342-5. PubMed ID: 15341684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor antagonists for heart failure.
    Richards AM
    Expert Opin Pharmacother; 2011 Dec; 12(18):2801-15. PubMed ID: 22082128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone reduces morbidity and mortality after acute MI.
    Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244
    [No Abstract]   [Full Text] [Related]  

  • 9. Eplerenone in patients with acute myocardial infarction complicated by heart failure.
    Ramaraj R
    Hypertension; 2008 Dec; 52(6):e147; author reply e48. PubMed ID: 18936342
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers.
    Ahmed A
    J Am Coll Cardiol; 2003 May; 41(10):1851-2. PubMed ID: 12767683
    [No Abstract]   [Full Text] [Related]  

  • 11. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 14. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
    Aaronson K
    Health News; 2003 May; 9(5):4. PubMed ID: 12739453
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone made no difference to patients with mild diastolic heart failure.
    BMJ; 2013 Feb; 346():f1290. PubMed ID: 23447350
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aldosterone antagonists: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Yamamoto T
    Nihon Rinsho; 2007 May; 65 Suppl 5():102-6. PubMed ID: 17571373
    [No Abstract]   [Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.